Taking nutrition from personalization to precision | AgriLife Today – AgriLife Today

The theme for this years National Nutrition Month is Personalize Your Plate, and Texas A&M AgriLife is taking this opportunity to emphasize the importance of individualized diet and precision nutrition to meet specific health needs and goals. Diet is an underlying risk factor for many chronic diseases and, as such, can also serve as part of the solution, said Rebecca Seguin-Fowler, associate director ofTexas A&M AgriLife Research and associate professor inthe Department of Nutrition at Texas A&Ms College of Agriculture and Life Sciences, Bryan-College Station.

Read more
When will cell-cultured meat reach price parity with conventional meat? – FoodNavigator-USA.com

The studies make clear that achieving costs below $7 per kg will require higher-density cell cultures, more efficient use of food-grade media, food-grade equipment in facilities, significant but attainable cost reductions in recombinant protein and growth factor production, and more relaxed payback time criteria for capital expenditures, says the Good Food Institute (GFI), which commissioned the studies along with Belgian animal rights advocacy group GAIA. The two studies - atechno-economic assessment (TEA)and a life cycle assessment (LCA)- model the costs and environmental impacts of a hypothetical commercial-scale cell-cultured meat facility churning out 10,000 metric tons of ground meat a year at a temperature of around 37C (98.6F) in 2030

Read more
Poseida Therapeutics Reports Program Updates and Financial Results for the Fourth Quarter and Full Year 2020 – PRNewswire

SAN DIEGO, March 11, 2021 /PRNewswire/ --Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced program updates and financial results for the fourth quarter and full year ended December 31, 2020.

Read more
Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the…

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for VX-880 and that the company has initiated a clinical trial for VX-880 in patients who have type 1 diabetes (T1D) with severe hypoglycemia and impaired hypoglycemic awareness

Read more
Bone Marrow-Derived Stem Cells (BMSCS) Market To Witness Relatively Significant Growth During Forecast to 2027 The Courier – The Courier

TheBone Marrow-Derived Stem Cells (BMSCS) Marketresearch report thoroughly explains each and every aspect related to the Global Bone Marrow-Derived Stem Cells (BMSCS) Market, which facilitates the reports reader to study and evaluate the upcoming market trend and execute the analytical data to promote the business. Bone Marrow-Derived Stem Cells (BMSCS) Market Insight: Bone marrow-derivedstem cells(BMSCS) market is expected to gain market growth in the forecast period of 2020 to 2027

Read more
Cell Banking Outsourcing Market 2021 By Size, Key Players Profile, In-Depth Qualitative Insights, Future Plans, COVID-19 Market Outlook, Industry…

Global Cell Banking Outsourcing Market is valued at USD 7122.6 Million in 2019 and expected to reach USD 18489.6 Million by 2026 with the CAGR of 14.6% over the forecast period. Rising prevalence of cancer and infectious chronic disorders couples with growing demand for research and development in therapy viral cell banking and viral cell banking safety testing are expected to propel the growth of the Global Cell Banking Outsourcing Market

Read more
Chemotherapy-Induced Myelosuppression Treatment Market 2021 Revenue, COVID Impact Analysis Report, I – PharmiWeb.com

A new study by FMI reveals that the chemotherapy-induced myelosuppression treatment market is expected to grow at a subdued 3% y-o-y in 2019. Valued at nearly US$ 7 billion in 2018, gains are likely to be driven by a combination of multipronged factors, including, The FMI study finds that growth factor drugs continued to garner highest revenues in thechemotherapy-induced myelosuppression treatment market. In 2018, over 73% of the chemotherapy-induced myelosuppression treatment market revenues were consolidated in the growth factors

Read more